New Horizons in the Management of ALS: Leveraging Emerging Therapeutic Breakthroughs to Make Informed Decisions

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of ALS, including
how to translate the most recent data into clinical and administrative practice.

These are archives of live webinars held between January 15 and January 23, 2020.
If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

Each session has its own specific valid dates

This series is supported by educational grants from
Biogen and Mitsubishi Tanabe Pharma America

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.


Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. An estimated 20,000 people in the US are living with ALS. Although most patients with ALS die within 3 to 5 years after symptoms first appear, about 20% of patients with ALS will live 5 years, 10% will live 10 years, and about 5% will live 20 years or more. Currently, there is no cure for ALS, but fortunately, the treatment paradigm has expanded in recent years, giving healthcare professionals many more options in managing symptoms and delaying progression.

Improving Patient Adherence and Quality of Life in ALS: New Insights on Optimizing Adverse Event Management and Patient Health Maintenance

  1. Implement effective strategies to improve medication management and patient health maintenance
  2. Identify and overcome the current challenges of providers and payers in relation to ALS treatment access
  3. Explore strategies to monitor and manage adverse events associated with available and emerging treatments in ALS in order to improve patient adherence and quality of life
  4. Optimize the management of symptoms associated with ALS with novel treatment strategies
          Physician, Nursing and CMCN credits valid to February 1, 2022

Comparative Effectiveness and Coordinated Care in ALS: What Managed Care Needs to Know about Novel Therapies

  1. Analyze cost management practices to mitigate expenditures while improving outcomes in patients with ALS
  2. Discuss the managed care considerations of new and emerging therapies and explore where these agents fit in the ALS management paradigm
  3. Identify practices that managed care professionals can use both now and in the future to help improve outcomes, mitigate disease progression and ensure appropriate and timely access to emerging therapies in ALS
  4. Transform therapeutic advances and resource utilization data into informed plan decisions and formulary discussions
          Physician, Nursing and CMCN credits valid to February 1, 2022

A Deeper Look into Available and Emerging Therapies in the Management of Amyotrophic Lateral Sclerosis (ALS): Individualizing Treatment for Improved Clinical and Economic Outcomes

  1. Examine the pathophysiology and degenerative effects of amyotrophic lateral sclerosis (ALS)
  2. Discuss the impact, direct and indirect costs, and unmet needs of ALS and the value of early diagnosis
  3. Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of ALS
  4. Optimize the management of symptoms associated with ALS with novel treatment strategies
  5. Review recently approved therapies for ALS that are designed to slow the loss of physical function
  6. Analyze the role of novel antisense oligonucleotides (ASO) in the management of ALS patients that have a mutation in the SOD1 gene
          Physician, Nursing and CMCN credits valid to February 1, 2022